Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

33
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
33
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

37
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
37
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.7K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.7K
Modified-Release Drug Delivery Systems: Stimuli-Activated01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

32
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
32
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

47
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
47
Principles of Drug Action01:24

Principles of Drug Action

9.0K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
9.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Folate Receptor β-Targeted TLR7 Agonist Significantly Augments Checkpoint Inhibitor Potencies by Reprogramming Tumor-Associated Macrophages and Myeloid-Derived Suppressor Cells.

Journal of medicinal chemistry·2026
Same author

Folate receptor β-targeted Positron emission tomography imaging of activated macrophages in experimental myocardial infarction.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology·2026
Same author

[<sup>18</sup>F]Fluoronicotinic-Acid-Conjugated Folate as a Novel Candidate Positron Emission Tomography Tracer for Inflammation.

ACS omega·2026
Same author

Design of a Pan-Tumor Fluorescence Imaging Cocktail for Fluorescence-Guided Surgery.

Bioconjugate chemistry·2025
Same author

Comparing Two Folate Receptor β‑Targeted Tracers in a Rat Model of Experimental Autoimmune Myocarditis.

ACS pharmacology & translational science·2025
Same author

Folate receptor β performs an immune checkpoint function in activated macrophages.

Frontiers in immunology·2025

Related Experiment Video

Updated: Feb 23, 2026

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

8.1K

Ligand-Targeted Drug Delivery.

Madduri Srinivasarao1, Philip S Low1

  • 1Purdue Institute for Drug Discovery, Purdue University , West Lafayette, Indiana 47907, United States.

Chemical Reviews
|September 13, 2017
PubMed
Summary
This summary is machine-generated.

Designing ligand-targeted drugs (LTDs) requires careful selection of targeting ligands to maximize therapeutic efficacy and minimize toxicity. This approach enhances drug safety and regulatory approval probability by targeting diseased cells specifically.

More Related Videos

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

11.3K
In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

8.1K

Related Experiment Videos

Last Updated: Feb 23, 2026

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

8.1K
Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

11.3K
In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

8.1K

Area of Science:

  • Pharmacology and Drug Development
  • Molecular Targeting and Drug Delivery

Background:

  • Drug safety and efficacy are paramount for regulatory approval.
  • Targeted drug delivery systems aim to improve therapeutic outcomes by selectively binding to diseased cells.

Purpose of the Study:

  • To review the design criteria for ligand-targeted drugs (LTDs) to achieve optimal potency and minimal toxicity.
  • To explore the use of imaging agents conjugated to targeting ligands for patient selection.

Main Methods:

  • Summarizing design criteria for individual LTD components: targeting ligand, spacer, cleavable linker, and therapeutic warhead.
  • Considering disease-specific limitations and characteristics impacting drug delivery.
  • Leveraging genomic and transcriptomic data for disease-specific target identification.

Main Results:

  • Successful LTD design necessitates careful consideration of each component's properties.
  • Patient selection using imaging agents can enhance therapeutic efficacy.
  • Disease-specific challenges require tailored drug delivery strategies.

Conclusions:

  • Innovating safe and effective LTDs is increasingly feasible due to advances in target identification and chemical synthesis.
  • Strategic design of LTDs holds significant promise for improving cancer therapy and other diseases.